2024
Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial
Xiong Y, Wang L, Pan Y, Wang M, Schwamm L, Duan C, Campbell B, Li S, Hao M, Wu N, Cao Z, Wu S, Li Z, Wang Y. Tenecteplase versus alteplase for acute ischaemic stroke in the elderly patients: a post hoc analysis of the TRACE-2 trial. Stroke And Vascular Neurology 2024, svn-2023-003048. PMID: 38858097, DOI: 10.1136/svn-2023-003048.Peer-Reviewed Original ResearchSymptomatic intracranial haemorrhageAcute ischaemic strokeModified Rankin ScaleElderly patientsPost hoc analysisAlteplase groupTenecteplase groupHoc analysisAlternative to alteplaseModified Rankin scale 0Ischaemic strokeRisk-benefit profileNon-inferiority clinical trialBenefit-risk profileEfficacy outcomesProportion of participantsReperfusion therapyIntracranial haemorrhageClinical trialsRankin ScaleSymptom onsetTenecteplaseAlteplaseIntravenous thrombolyticsSafety outcomes
2022
Ischemic Stroke Systems of Care in California: Evolution in the Organization During the Mechanical Thrombectomy Era
Zachrison K, Hsia R, Li S, Reeves M, Camargo C, Yan Z, Onnela J, Schwamm L. Ischemic Stroke Systems of Care in California: Evolution in the Organization During the Mechanical Thrombectomy Era. Stroke Vascular And Interventional Neurology 2022, 2 DOI: 10.1161/svin.121.000206.Peer-Reviewed Original ResearchEndovascular thrombectomyStroke systemsHospital-level factorsOdds of transferLogistic regression modelsAlteplase useEVT proceduresStroke NetworkObservational studyTimely careRural hospitalsTrial dataHospitalPatientsHospital postsHospital pairsCarePatient transfer networksRegression modelsNumber of encountersLinear regressionThrombectomyAlteplaseRegressionGreater POST
2021
Thrombolysis in Mild Stroke
Asdaghi N, Romano J, Gardener H, Campo-Bustillo I, Purdon B, Khan Y, Gulati D, Broderick J, Schwamm L, Smith E, Saver J, Sacco R, Khatri P. Thrombolysis in Mild Stroke. Stroke 2021, 52: e586-e589. PMID: 34496619, DOI: 10.1161/strokeaha.120.033466.Peer-Reviewed Original ResearchConceptsNIHSS scoreClinical practiceHealth Stroke Scale scoreMild ischemic stroke patientsMedian NIHSS scoreTrial of thrombolysisStroke Scale scoreIschemic stroke patientsProportion of patientsBroad clinical practiceRoutine clinical practiceSyndromic severityTrial cohortStroke patientsMild strokeMild patientsNeurological syndromeAlteplasePatientsScale scoreLess severityMaRISSComparable deficitsNational InstituteSeverity
2020
Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs
Naidech A, Lawlor P, Xu H, Fonarow G, Xian Y, Smith E, Schwamm L, Matsouaka R, Prabhakaran S, Marinescu I, Kording K. Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs. Frontiers In Neurology 2020, 11: 961. PMID: 32982952, PMCID: PMC7492202, DOI: 10.3389/fneur.2020.00961.Peer-Reviewed Original ResearchTreatment thresholdOutcomes of patientsAcute ischemic strokeCohort of patientsPatient demographic characteristicsIschemic strokeControlled TrialsStroke interventionClinical outcomesClinical careEffective treatmentLarger sample sizeMedical interventionsPatientsDemographic characteristicsGold standardAlteplaseInterventionTreatmentContinuous variablesOutcomesLimited populationSample sizeTreatment timePotential reasonsAcute ischemic stroke: improving access to intravenous tissue plasminogen activator
Turner A, Schwamm L, Etherton M. Acute ischemic stroke: improving access to intravenous tissue plasminogen activator. Expert Review Of Cardiovascular Therapy 2020, 18: 277-287. PMID: 32323590, DOI: 10.1080/14779072.2020.1759422.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeIschemic stroke patientsIschemic strokeStroke patientsTreatment windowAcute ischemic stroke patientsIntravenous tissue plasminogen activatorTreatment ratesUnknown symptom onsetAcute stroke careTissue plasminogen activatorQuality improvement initiativesHealth care resourcesUnited States FoodStroke outcomeSymptom onsetStroke careStroke specialistsStroke systemsTelestroke networkDrug AdministrationAlteplasePatientsPlasminogen activatorStates Food
2017
Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke
Yaghi S, Willey JZ, Cucchiara B, Goldstein JN, Gonzales NR, Khatri P, Kim LJ, Mayer SA, Sheth KN, Schwamm LH. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke. Stroke 2017, 48: e343-e361. PMID: 29097489, DOI: 10.1161/str.0000000000000152.Peer-Reviewed Original ResearchConceptsSymptomatic intracranial hemorrhageAcute ischemic strokeIschemic strokeSystemic thrombolysisCase seriesIntravenous thrombolytic therapyMainstay of treatmentSmall case seriesTreatment of patientsBlood-brain barrierWriting group membersHemorrhagic transformationIntravenous alteplaseFeared complicationSevere complicationsPrompt diagnosisRandomized trialsThrombolytic therapyIntracranial hemorrhageRetrospective studyRisk factorsEarly correctionAlteplaseStrokeLiterature review
2011
A Qualitative Assessment of Practices Associated With Shorter Door-to-Needle Time for Thrombolytic Therapy in Acute Ischemic Stroke
Olson D, Constable M, Britz G, Lin C, Zimmer L, Schwamm L, Fonarow G, Peterson E. A Qualitative Assessment of Practices Associated With Shorter Door-to-Needle Time for Thrombolytic Therapy in Acute Ischemic Stroke. Journal Of Neuroscience Nursing 2011, 43: 329-336. PMID: 22089410, DOI: 10.1097/jnn.0b013e318234e7fb.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeNeedle timeIschemic strokeStroke patientsGoal of doorQualitative telephone interviewsThrombolytic therapyEarly treatmentImproved outcomesTPA deliveryRapid triageHermeneutic phenomenological frameworkTelephone interviewsPatientsU.S. hospitalsStrokeHospitalFaster treatmentTreatmentNovel factorOvercoming barriersElicit strategiesAlteplaseQualitative assessmentTherapy